Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENGPHARMACEUTICALCO., LTD.
Securities code: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) securities abbreviation: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) Announcement No.: 2022065
Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
Announcement on the resolution of the seventh extraordinary meeting of the Fifth Board of directors in 2022
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and completeness of its contents.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) (hereinafter referred to as “the company”) the Fifth Board of directors
The seventh interim meeting of the board of directors in 2022 voted by communication on May 23, 2022
Held in a manner. The Securities Department of the company has sent e-mail, wechat
Notify all directors by telephone. The meeting was convened by Ms. Zhou Xiaoli, the chairman of the board of directors. There were 6 directors who should attend the meeting and 6 directors who actually attended the meeting. The number of voting participants and the convening and convening procedures of this meeting comply with the relevant provisions of the company law and the articles of association, and the meeting is legal and effective. The meeting considered and adopted the following proposals:
1、 Proposal on Amending the articles of Association
For details of this proposal, please refer to the website of China Securities Journal, Shanghai Securities News, securities times, securities daily and Shanghai Stock Exchange on the date of disclosure of this announcement（ http://www.sse.com.cn. ）Company Announcement No. 2022066 published.
Voting status of the proposal: 6 in favor, 0 against, 0 abstention, passed
Yes.
2、 Proposal on convening the first extraordinary general meeting of shareholders in 2022
The board of directors decided to hold the second meeting of the company in 2022 on Wednesday, June 8, 2022
An extraordinary general meeting of shareholders. See the website of Shanghai stock exchange for details（ http://www.sse.com.cn. ）And the company’s Announcement No. 2022067 published in the securities times, Shanghai Securities News, China Securities News and Securities Daily.
Voting status of the proposal: 6 in favor, 0 against, 0 abstention, passed
Yes.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENGPHARMACEUTICALCO., LTD.
Among the above proposals, the first one needs to be submitted to the general meeting of shareholders of the company for deliberation. It is hereby announced
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) board of directors
May 23, 2022
